Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00963053 · ClinicalTrials.gov registry record · Phase 2
VA111913 Dysmenorrhoea Efficacy and Safety Proof of Concept
A Phase 2 study of Primary Dysmenorrhea, sponsored by Vantia.
- Completed
- Registry status
- Phase 2
- Development phase
- 146
- Enrollment target
- 4
- Study locations
NCT00963053 is a Phase 2 study of Primary Dysmenorrhea that has completed, run by Vantia. The registered enrollment target is 146 participants. The trial reports 4 study locations across 4 states.
The verdict
NCT00963053, a Phase 2 study of Primary Dysmenorrhea, has completed, sponsored by Vantia.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 146 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of the study is to investigate how effective VA111913 is at preventing menstrual pain in women with primary dysmenorrhoea.
Conditions Studied
Interventions
- DRUG VA111913 TS and placebo
Study Locations (4)
Arizona
- Pivotal Research Centers - Peoria
Texas
- Premier Research Group - Austin
Utah
- Jean Brown Research - Salt Lake City
Other
- Bio-Kinetic Europe Limited - Belfast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2009-08 |
| Est. Completion | 2010-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00963053
The ClinicalTrials.gov registry entry for NCT00963053 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 146 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vantia, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Primary Dysmenorrhea appearing as the primary indexed condition, and to 1 intervention - of which VA111913 TS and placebo is the first listed.
NCT00963053 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Arizona, Texas, Utah.
Frequently Asked Questions
What is clinical trial NCT00963053 about?
NCT00963053 is a clinical study titled "VA111913 Dysmenorrhoea Efficacy and Safety Proof of Concept". The purpose of the study is to investigate how effective VA111913 is at preventing menstrual pain in women with primary dysmenorrhoea.
What is the current status of trial NCT00963053?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 146 participants. The study started on 2009-08. Estimated completion is 2010-11.
What conditions does trial NCT00963053 study?
This clinical trial studies the following conditions: Primary Dysmenorrhea.
What interventions are being tested in trial NCT00963053?
The interventions under investigation include: VA111913 TS and placebo (DRUG).
Who is sponsoring clinical trial NCT00963053?
This trial is sponsored by Vantia, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00963053 being conducted?
This trial has 4 study locations across Arizona, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Dysmenorrhea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.